Your browser doesn't support javascript.
loading
Bortezomib for Refractory Immune-Mediated Thrombocytopenia Purpura.
Beckman, Joan D; Rollins-Raval, Marian A; Raval, Jay S; Park, Yara A; Mazepa, Marshall; Ma, Alice.
Afiliação
  • Beckman JD; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
  • Rollins-Raval MA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Raval JS; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Park YA; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Mazepa M; Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, NC.
  • Ma A; Division of Hematology/Oncology, Department of Medicine, University of North Carolina, Chapel Hill, NC.
Am J Ther ; 25(2): e270-e272, 2018.
Article em En | MEDLINE | ID: mdl-29293474
The treatment of refractory immune-mediated thrombocytopenia purpura (ITP) can be challenging. This case report describes treatment of refractory ITP with bortezomib, a proteasome inhibitor. This strategy has been successful in relapsing thrombotic thrombocytopenic purpura but is a novel therapeutic approach for ITP. Further research use of proteasome inhibition in refractory ITP may be warranted.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Inibidores de Proteassoma / Bortezomib Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Púrpura Trombocitopênica Idiopática / Inibidores de Proteassoma / Bortezomib Limite: Female / Humans / Middle aged Idioma: En Ano de publicação: 2018 Tipo de documento: Article